<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00901550</url>
  </required_header>
  <id_info>
    <org_study_id>ERA_2008</org_study_id>
    <nct_id>NCT00901550</nct_id>
  </id_info>
  <brief_title>The Chinese University of Hong Kong Early Arthritis Study</brief_title>
  <acronym>ERA</acronym>
  <official_title>The Chinese University of Hong Kong Early Arthritis Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:&#xD;
&#xD;
        1. To ascertain whether the quantitative assessment of enhancing synovial volume and&#xD;
           perfusion indices on serial Magnetic Resonance Imaging (MRI) examination are useful&#xD;
           indicators of responsiveness to treatment in early Rheumatoid Arthritis (RA) using&#xD;
           biologic therapy and Methotrexate (MTX) compared with Methotrexate(MTX) alone.&#xD;
&#xD;
        2. To assess the cost-effectiveness of Tumor Necrosis Factor (TNF) blockers compared with&#xD;
           Methotrexate(MTX) monotherapy for Rheumatoid Arthritis(RA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a 24-week open-label randomized study. Forty patients are randomly assigned to&#xD;
      receive either combination infliximab plus Methotrexate(MTX) (n=20) or Methotrexate(MTX)&#xD;
      alone (n=20)&#xD;
&#xD;
      All participants received oral Methotrexate(MTX), starting at 7.5 mg/week. In patients with&#xD;
      persistent tender or swollen joints, the dose was escalated in a graduated manner (2.5&#xD;
      mg/week every 1-2 weeks) to 15 mg/week by week 4 or 20 mg/week by week 8 Patients in&#xD;
      combination group receive infliximab 3mg/kg at weeks 0, 2, and 6 and every 8 week thereafter.&#xD;
      Comprehensive assessment will be made on week 0, 12, 24.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the volume of enhancing synovitis measured by Magnetic Resonance Imaging(MRI) as it corresponds to active, inflamed tissue and is therefore expected to be a better marker of disease activity.</measure>
    <time_frame>week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in the synovitis grading and the perfusion indices</measure>
    <time_frame>24 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients achieving ACR and EULAR responses</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between the Magnetic Resonance Imaging(MRI) findings and changes on x-ray</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Methotrexate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A drug for RA patient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infliximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>for RA treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>All participants received oral Methotrexate(MTX), starting at 7.5 mg/week. In patients with persistent tender or swollen joints, the dose was escalated in a graduated manner (2.5 mg/week every 1-2 weeks) to 15 mg/week by week 4 or 20 mg/week by week 8</description>
    <arm_group_label>Methotrexate</arm_group_label>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>Patients in combination group receive infliximab 3mg/kg at weeks 0, 2, and 6 and every 8 week thereafter.</description>
    <arm_group_label>Infliximab</arm_group_label>
    <other_name>Remicade</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women, 18 years of age or older&#xD;
&#xD;
          -  Clinical diagnosis of RA with a duration not more than 24 months (Fulfilled the 1987&#xD;
             American College of Rheumatology (ACR) criteria for RA)&#xD;
&#xD;
          -  Patients at risk of developing persistent or erosive arthritis&#xD;
&#xD;
          -  DAS 28 ≥ 3.2&#xD;
&#xD;
          -  Prednisolone &lt; 10mg/day and started at least 4 weeks before baseline&#xD;
&#xD;
          -  Either has ESR ≥ 28, CRP ≥ 10, presence of rheumatoid factor or anti-CCP, present of&#xD;
             HLADRB*0401 or DRB1*0404, and radiographic erosions&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Little or no ability for self-care&#xD;
&#xD;
          -  Previous treatment with DMARDs other than antimalarials&#xD;
&#xD;
          -  Concomitant treatment with an experimental drug&#xD;
&#xD;
          -  Malignancy within the last 5 years&#xD;
&#xD;
          -  Bone marrow hypoplasia&#xD;
&#xD;
          -  Clinically significant renal disease ( serum creatinine level ≥ 150µmol/L) or&#xD;
             estimated creatinine clearance &gt; 75ml/min, alanine aminotransferase (ALT) exceeds the&#xD;
             upper limit of normal&#xD;
&#xD;
          -  History of any clinically significant adverse reaction to murine or chimeric proteins&#xD;
&#xD;
          -  History of TB in the last 5 years&#xD;
&#xD;
          -  Known to have hepatitis B, or hepatitis C&#xD;
&#xD;
          -  Had an opportunistic infection (e.g. herpes zoster, cytomegalovirus, Pneumocystis&#xD;
             carinii, aspergillosis, histoplasmosis, or mycobacteria other than TB) within 6 months&#xD;
             before screening&#xD;
&#xD;
          -  History or ongoing chronic or recurrent disease; renal infection, chest infection,&#xD;
             urinary tract infection, ulcer or skin wound&#xD;
&#xD;
          -  History of infected joint prosthesis and use of antibiotics for the joint&#xD;
&#xD;
          -  Received intravenous antibiotics within 30 days or oral antibiotics within 14 days for&#xD;
             screening&#xD;
&#xD;
          -  History of known demyelinating diseases (multiple sclerosis or optic neuritis)&#xD;
&#xD;
          -  Current signs or symptoms of severe diseases (renal, hepatic, hematologic, endocrine,&#xD;
             pulmonary, cardiac, neurologic, etc)&#xD;
&#xD;
          -  History or concurrent CHF&#xD;
&#xD;
          -  History of lymphoproliferative disease, splenomegaly&#xD;
&#xD;
          -  Female of childbearing potential, unwilling to use adequate contraception during the&#xD;
             study&#xD;
&#xD;
          -  Current or recent ( within the past 3 months) pregnancy and cancer&#xD;
&#xD;
          -  Active smoker, alcohol or drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edmund K Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Medicine and Therapeutics</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>May 13, 2009</study_first_submitted>
  <study_first_submitted_qc>May 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2009</study_first_posted>
  <last_update_submitted>July 31, 2012</last_update_submitted>
  <last_update_submitted_qc>July 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Lai-Shan Tam</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>MTX</keyword>
  <keyword>anti-TNF</keyword>
  <keyword>Early RA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

